Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-Putative lipid scramblase CLPTM1 Antibody (9W398) is a Rabbit antibody targeting Putative lipid scramblase CLPTM1. Anti-Putative lipid scramblase CLPTM1 Antibody (9W398) can be used in FCM, ICC/IF, IHC, IHC-Fr, WB.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 50 μL | $369 | 7-10 days | 7-10 days | |
| 100 μL | $677 | 7-10 days | 7-10 days |
| Description | Anti-Putative lipid scramblase CLPTM1 Antibody (9W398) is a Rabbit antibody targeting Putative lipid scramblase CLPTM1. Anti-Putative lipid scramblase CLPTM1 Antibody (9W398) can be used in FCM, ICC/IF, IHC, IHC-Fr, WB. |
| Synonyms | N14, HS9 |
| Ig Type | IgG |
| Clone | 9W398 |
| Reactivity | Human |
| Specificity | Putative lipid scramblase CLPTM1 |
| Verified Activity | Western blot analysis of CLPTM1 expression in HepG2 cell lysate. |
| Application | |
| Recommended Dose | FCM: 1:20-1:100; ICC/IF: 1:50-1:200; IHC: 1:100-1:200; IHC-Fr: 1:50-1:200; WB: 1:1000-1:2000 |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Purification | Affinity-chromatography |
| Appearance | Liquid |
| Formulation | Supplied in 10 mM phosphate buffered saline, pH 7.4, 150 mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Research Background | Involved in GABAergic but not glutamatergic transmission. Binds and traps GABAA receptors in the endoplasmic reticulum (ER). Modulates postsynaptic GABAergic transmission, and therefore inhibitory neurotransmission, by reducing the plasma membrane expression of these receptors. Altered GABAergic signaling is one among many causes of cleft palate. |
| Conjucates | Unconjugated |
| Immunogen | A synthesized peptide: human Putative lipid scramblase CLPTM1 |
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.